IBDEI0W9 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15675,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,15675,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,15676,0)
 ;;=205.11^^81^946^21
 ;;^UTILITY(U,$J,358.3,15676,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15676,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,15676,1,5,0)
 ;;=5^CML,In Remission
 ;;^UTILITY(U,$J,358.3,15676,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,15677,0)
 ;;=289.0^^81^946^55
 ;;^UTILITY(U,$J,358.3,15677,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15677,1,4,0)
 ;;=4^289.0
 ;;^UTILITY(U,$J,358.3,15677,1,5,0)
 ;;=5^Erthryocytosis, Secondary
 ;;^UTILITY(U,$J,358.3,15677,2)
 ;;=^186856
 ;;^UTILITY(U,$J,358.3,15678,0)
 ;;=238.4^^81^946^109
 ;;^UTILITY(U,$J,358.3,15678,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15678,1,4,0)
 ;;=4^238.4
 ;;^UTILITY(U,$J,358.3,15678,1,5,0)
 ;;=5^Polycytheria Rubra Vera
 ;;^UTILITY(U,$J,358.3,15678,2)
 ;;=^96105
 ;;^UTILITY(U,$J,358.3,15679,0)
 ;;=V58.61^^81^946^126
 ;;^UTILITY(U,$J,358.3,15679,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15679,1,4,0)
 ;;=4^V58.61
 ;;^UTILITY(U,$J,358.3,15679,1,5,0)
 ;;=5^Warfarin/Coumadin Use
 ;;^UTILITY(U,$J,358.3,15679,2)
 ;;=Warfarin/Coumadin Use^303459
 ;;^UTILITY(U,$J,358.3,15680,0)
 ;;=282.49^^81^946^117
 ;;^UTILITY(U,$J,358.3,15680,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15680,1,4,0)
 ;;=4^282.49
 ;;^UTILITY(U,$J,358.3,15680,1,5,0)
 ;;=5^Thalassemia NEC
 ;;^UTILITY(U,$J,358.3,15680,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,15681,0)
 ;;=289.89^^81^946^15
 ;;^UTILITY(U,$J,358.3,15681,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15681,1,4,0)
 ;;=4^289.89
 ;;^UTILITY(U,$J,358.3,15681,1,5,0)
 ;;=5^Blood Diseases NEC
 ;;^UTILITY(U,$J,358.3,15681,2)
 ;;=^329887
 ;;^UTILITY(U,$J,358.3,15682,0)
 ;;=238.79^^81^946^88
 ;;^UTILITY(U,$J,358.3,15682,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15682,1,4,0)
 ;;=4^238.79
 ;;^UTILITY(U,$J,358.3,15682,1,5,0)
 ;;=5^Lymph/Hematopoietic Tissue NEC
 ;;^UTILITY(U,$J,358.3,15682,2)
 ;;=^334033
 ;;^UTILITY(U,$J,358.3,15683,0)
 ;;=287.30^^81^946^110
 ;;^UTILITY(U,$J,358.3,15683,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15683,1,4,0)
 ;;=4^287.30
 ;;^UTILITY(U,$J,358.3,15683,1,5,0)
 ;;=5^Primary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,15683,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,15684,0)
 ;;=288.09^^81^946^8
 ;;^UTILITY(U,$J,358.3,15684,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15684,1,4,0)
 ;;=4^288.09
 ;;^UTILITY(U,$J,358.3,15684,1,5,0)
 ;;=5^Agranulocytosis
 ;;^UTILITY(U,$J,358.3,15684,2)
 ;;=^334042
 ;;^UTILITY(U,$J,358.3,15685,0)
 ;;=V10.21^^81^946^61
 ;;^UTILITY(U,$J,358.3,15685,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15685,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,15685,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,15685,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,15686,0)
 ;;=284.2^^81^946^106
 ;;^UTILITY(U,$J,358.3,15686,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15686,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,15686,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,15686,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,15687,0)
 ;;=202.40^^81^946^76
 ;;^UTILITY(U,$J,358.3,15687,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15687,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,15687,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,15687,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,15688,0)
 ;;=287.49^^81^946^118
 ;;^UTILITY(U,$J,358.3,15688,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15688,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,15688,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,15688,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,15689,0)
 ;;=180.9^^81^946^29
 ;;
 ;;$END ROU IBDEI0W9
